肛管癌的治疗结果:单一机构的经验。

PubMed ID
发表日期 年月

原始出处 沙特医学年鉴
Annals of Saudi medicine
作者 El-Haddad  Mostafa  Ahmed  Raef S  Al-Suhaibany  Abdallah  Al-Hazza  Manal  Al-Sanae  Nasser  Al-Jabbar  Alaa Abd  Hamoud  Samar  Ashaary  Loay  Bazerbashy  Shouky  Balaraj  Khaled 

文献标题 肛管癌的治疗结果:单一机构的经验。
Anal canal carcinoma treatment results: the experience of a single institution.

文献摘要 BACKGROUND AND OBJECTIVES

在20世纪80年代中期以前,治疗肛管癌的首选方法是腹会阴切除术。目前,联合放化疗是治疗的标准。目的分析联合放化疗治疗肛管癌的疗效。

DESIGN AND SETTING

回顾性分析了金费萨尔专科医院和研究中心(KFSHRC)12年(1993年至2005年)当地癌症登记处的数据。

METHODS

我们确定了确诊为肛管鳞状细胞癌的患者。

RESULTS

在确定的40名患者中,33名被认为符合我们的分析条件。所有患者均采用同步放化疗加强制停药(MTB)治疗,局部复发10例(30%)。5年无进展生存率(PFS)为50.9%;5年总生存率(OS)为73.4%。II期患者的中位PFS期为10年,直到最后一次随访才复发。IIIA期和IIIB期患者的PFS无统计学差异,分别为44.7%和45%(P=0.8)。按T分期,5年PFS为T1,66%;T2,71%;T3,59%;T4,30%(P>0.05)。所有患者的5年无结肠造口生存率(CFS)为74%。远处转移4例。

CONCLUSION

联合放化疗治疗肛管癌在局部控制和保留括约肌方面是有效的。接受MTB治疗的患者的PFS、OS和CFS的五年估计值与大多数非MTB系列的测定值惊人地具有可比性。然而,我们报告了更高的局部失败率,为此我们正在重新评估我们的治疗方案。


BACKGROUND AND OBJECTIVES

Prior to the mid-1980s, the treatment of choice for anal cancer was abdominoperineal resection. Currently, combined chemoradiation is the standard of care. Or objective was to analyze results of treatment for anal canal carcinoma treated with combined chemoradiation.

DESIGN AND SETTING

Retrospective review of data in local cancer registry at King Faisal Specialist Hospital and Research Centre (KFSHRC) from a 12-year period (1993 to 2005).

METHODS

We identified patients with confirmed diagnosis of anal canal squamous cell carcinoma.

RESULTS

Of 40 patients identified, 33 were considered eligible for our analysis. All patients were treated by concurrent chemoradiation with mandatory treatment break (MTB) There were 10 (30%) local recurrences. Five-year progression-free survival (PFS) was 50.9%; overall survival (OS) at 5 years was 73.4%. Patients with stage II disease had a median PFS period of 10 years, with no relapses until their last follow-up. There was no statistically significant difference in PFS between patients with stage IIIA disease and those with stage IIIB disease-44.7% and 45%, respectively (P=.8). Five-year PFS according to 'T' stages was as follows: T1, 66%; T2, 71%; T3, 59%; T4, 30% (P>.05). The 5-year colostomy-free survival (CFS) for all patients was 74%. Distant metastases were observed in 4 patients.

CONCLUSION

Combined chemoradiation in treatment of anal cancer is effective in terms of local control and sphincter preservation. Five-year estimates of PFS, OS, as well as CFS, in patients treated with a MTB were surprisingly comparable to those determined in most non-MTB series. However, we reported a higher local failure rate, for which we are reevaluating our treatment protocol.


获取全文 10.4103/0256-4947.77488